Literature DB >> 30321869

Uterine Leiomyosarcoma.

Ingolf Juhasz-Böss, Lena Gabriel, Rainer M Bohle, Lars C Horn, Erich-Franz Solomayer, Georg-Peter Breitbach.   

Abstract

Uterine leiomyosarcoma (uLMS) is a rare entity among malignant gynecologic tumors with a very unfavorable prognosis and the highest prevalence in the pre- and peri-menopause. Only early-stage tumors have an acceptable prognosis, provided the patient has been treated without injuring the uterus. uLMS is often diagnosed accidentally and the correct diagnosis ishampered by equivocal features similar to the far more frequent benign uterine fibroids. Surgery is the basis of therapy, and it should be done in order to remove the uterus intact. As vaginal, abdominal, and endoscopic surgery - possibly including morcellation - are the methods of choice for the treatment of uterine fibroids, pre-operatively undiagnosed leiomyosarcoma detected by pathologic examination will have a worsened prognosis. Systemic treatment and radiotherapy are of no proven value in the adjuvant setting. Thus, there is strong need for a reliable pre-operative risk score for leiomyosarcoma in order to justify diagnostic means beyond clinical routine and to choose the correct surgical pathway. The clinical problems in the diagnosis of leiomyosarcoma and treatment are exemplified by a case report of a 30-year-old childless patient. Diagnostic tools as well as treatment options in adjuvant and palliative situations are reviewed.
© 2018 S. Karger GmbH, Freiburg.

Entities:  

Keywords:  Diagnosis; Leiomyosarcoma; Surgery; Therapy; Uterus

Mesh:

Year:  2018        PMID: 30321869     DOI: 10.1159/000494299

Source DB:  PubMed          Journal:  Oncol Res Treat        ISSN: 2296-5270            Impact factor:   2.825


  8 in total

1.  Prognostic factors and survival of patients with uterine sarcoma: a German unicenter analysis.

Authors:  Alexandra Huss; Maximilian Klar; Mir Fuad Hasanov; Ingolf Juhasz-Böss; Michaela Bossart
Journal:  Arch Gynecol Obstet       Date:  2022-07-03       Impact factor: 2.344

Review 2.  MR Imaging of uterine sarcomas: a comprehensive review with radiologic-pathologic correlation.

Authors:  Filipa Alves E Sousa; Joana Ferreira; Teresa Margarida Cunha
Journal:  Abdom Radiol (NY)       Date:  2021-09-01

3.  Uterine leiomyosarcoma diagnosis after treatment of presumed uterine fibroid with the high-intensity focused ultrasound: a case description.

Authors:  Sha Wang; Hua Duan; Xiaoying Zhang; Bohan Li
Journal:  Quant Imaging Med Surg       Date:  2022-06

4.  The role of postoperative radiotherapy in patients with uterine sarcomas: A PSM-IPTW analysis based on SEER database.

Authors:  Zhimin Hao; Sufen Yang
Journal:  Front Surg       Date:  2022-08-09

Review 5.  Molecular Insights in Uterine Leiomyosarcoma: A Systematic Review.

Authors:  Radmila Sparić; Mladen Andjić; Ivana Babović; Lazar Nejković; Milena Mitrović; Jelena Štulić; Miljan Pupovac; Andrea Tinelli
Journal:  Int J Mol Sci       Date:  2022-08-27       Impact factor: 6.208

Review 6.  Genomic alterations in gynecological malignancies: histotype-associated driver mutations, molecular subtyping schemes, and tumorigenic mechanisms.

Authors:  Seiichi Mori; Osamu Gotoh; Kazuma Kiyotani; Siew Kee Low
Journal:  J Hum Genet       Date:  2021-06-07       Impact factor: 3.172

Review 7.  MRI findings in-between leiomyoma and leiomyosarcoma: a Rad-Path correlation of degenerated leiomyomas and variants.

Authors:  Vlad Bura; Roxana Maria Pintican; Reka Emma David; Helen Clare Addley; Janette Smith; Mercedes Jimenez-Linan; Janice Lee; Susan Freeman; Carmen Georgiu
Journal:  Br J Radiol       Date:  2021-07-21       Impact factor: 3.629

8.  Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System.

Authors:  Fenfen Zhang; Yao Liu; Quan Quan; Yu Meng; Xiaoling Mu
Journal:  Cancer Manag Res       Date:  2021-06-14       Impact factor: 3.989

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.